BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1643 related articles for article (PubMed ID: 2547513)

  • 1. ras oncogenes in human cancer: a review.
    Bos JL
    Cancer Res; 1989 Sep; 49(17):4682-9. PubMed ID: 2547513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ras gene family in human non-small-cell lung cancer.
    Slebos RJ; Rodenhuis S
    J Natl Cancer Inst Monogr; 1992; (13):23-9. PubMed ID: 1327034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.
    Rosell R; Li S; Skacel Z; Mate JL; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A
    Oncogene; 1993 Sep; 8(9):2407-12. PubMed ID: 8395679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence of ras mutations in human lung cancer. Minireview.
    Vachtenheim J
    Neoplasma; 1997; 44(3):145-9. PubMed ID: 9372854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid detection of ras oncogenes in human tumors: applications to colon, esophageal, and gastric cancer.
    Jiang W; Kahn SM; Guillem JG; Lu SH; Weinstein IB
    Oncogene; 1989 Jul; 4(7):923-8. PubMed ID: 2666911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ras and human tumors.
    Rodenhuis S
    Semin Cancer Biol; 1992 Aug; 3(4):241-7. PubMed ID: 1421168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular staging of non-small cell lung cancer according to K-ras genotypes.
    Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez JJ; Moreno I; Maurel J; López MP; Abad A; de Anta JM
    Clin Cancer Res; 1996 Jun; 2(6):1083-6. PubMed ID: 9816271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review.
    Minamoto T; Mai M; Ronai Z
    Cancer Detect Prev; 2000; 24(1):1-12. PubMed ID: 10757118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.
    Rodenhuis S; Slebos RJ; Boot AJ; Evers SG; Mooi WJ; Wagenaar SS; van Bodegom PC; Bos JL
    Cancer Res; 1988 Oct; 48(20):5738-41. PubMed ID: 3048648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma.
    Dammann R; Schagdarsurengin U; Liu L; Otto N; Gimm O; Dralle H; Boehm BO; Pfeifer GP; Hoang-Vu C
    Oncogene; 2003 Jun; 22(24):3806-12. PubMed ID: 12802288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.
    Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
    Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low mutational rate of K-ras codon 12 in singular bronchoscopy specimens in suspected lung cancer.
    Spasova I; Novotna H; Vachtenheim J; Bartosova H; Patek J; Hoserova V; Zatloukal P; Kinkor Z
    Neoplasma; 2005; 52(3):255-9. PubMed ID: 15875089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: comparison with immunohistochemistry and clinico-pathological features.
    Hilbe W; Dlaska M; Duba HC; Dirnhofer S; Eisterer W; Oberwasserlechner F; Mildner A; Schmid T; Kühr T; Wöll E
    Int J Oncol; 2003 Oct; 23(4):1121-6. PubMed ID: 12963994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
    Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
    Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer.
    Sekine I; Takami S; Guang SG; Yokose T; Kodama T; Nishiwaki Y; Kinoshita M; Matsumoto H; Ogura T; Nagai K
    Oncol Rep; 1998; 5(2):351-4. PubMed ID: 9468555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors.
    Younes N; Fulton N; Tanaka R; Wayne J; Straus FH; Kaplan EL
    Cancer; 1997 May; 79(9):1804-8. PubMed ID: 9128999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sensitive detection of K-ras oncogene codon 12 mutations by nested PCR using mismatched primers and selective digestion of non-mutated PCR fragments with restriction enzyme].
    Fukayama N; Sugano K; Kyogoku A; Nose H; Kondou H; Ohkura H
    Rinsho Byori; 1993 Sep; 41(9):1017-23. PubMed ID: 8254964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor.
    Hrasćan R; Pavelić K; Pavicić D; Krizanac S; Stajcer-Sittić V; Pecur L; Spaventi S; Klimpfinger M; Pavelić J
    Anticancer Res; 1996; 16(6B):3761-6. PubMed ID: 9042254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.